 PLYMOUTH MEETING, Pa., Aug. 4, 2021 PRNewswire -- INOVIO NASDAQ: INO, a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome MERS. 